Journal article
Prevalence of scabies and impetigo 3 years after mass drug administration with ivermectin and azithromycin
M Marks, L Romani, O Sokana, L Neko, R Harrington, T Nasi, H Wand, MJ Whitfeld, D Engelman, AW Solomon, JM Kaldor, AC Steer
Clinical Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2020
DOI: 10.1093/cid/ciz444
Abstract
Background. Ivermectin-based mass drug administration has emerged as a promising strategy for the control of scabies and impetigo in settings where the diseases are endemic. Current follow-up data are limited to 12 months for the majority of studies. Longer-term data are vital to inform the sustainability of interventions. Methods. We conducted a prevalence survey for scabies and impetigo in 10 villages in Choiseul Province of the Solomon Islands 36 months after a single round of ivermectin and azithromycin mass drug coadministration. In the primary analysis, we compared the prevalence of scabies and impetigo at 36 months to the prevalence at baseline. Results. At 36 months, the prevalence o..
View full abstractGrants
Funding Acknowledgements
The study was funded by the International Trachoma Initiative; the Murdoch Children's Research Institute, Australia; the Scobie and Claire Mackinnon Trust, Australia; and the Wellcome Trust. Ivermectin was provided at a reduced cost by Merck Sharp & Dohme Australia.